Oruka Therapeutics, Inc. Stock Split Ratio
Oruka Therapeutics, Inc. (ORKA) reported Stock Split Ratio of 14.30% for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-09.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2016-08-09
- Oruka Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2016-03-31 was 14.30%.
- Oruka Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2015 was 14.30%.
- Oruka Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2013 was 16.70%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2016-06-30 | 14.30% 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | 14.30% 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | 14.30% 10-K · filed 2016-03-17 | |||
| 2015-09-30 | 14.30% 10-Q · filed 2015-11-12 | |||
| 2013-12-31 | 16.70% 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |